Blood Biomarkers in Neurodegenerative Diseases
暂无分享,去创建一个
[1] K. Blennow,et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[2] K. Blennow,et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease , 2022, Nature Medicine.
[3] M. Carrillo,et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[4] C. Jack,et al. Performance of plasma phosphorylated tau 181 and 217 in the community , 2022, Nature Medicine.
[5] Suzanne E. Schindler,et al. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light , 2022, Neurology.
[6] A. Danek,et al. Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181 , 2022, Annals of neurology.
[7] F. Barkhof,et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease , 2022, The Journal of Prevention of Alzheimer's Disease.
[8] K. Blennow,et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity , 2022, Alzheimer's research & therapy.
[9] W. M. van der Flier,et al. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies , 2022, Neurology.
[10] Sara C. LaHue,et al. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology , 2022, Alzheimer's & dementia.
[11] W. M. van der Flier,et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 , 2021, Alzheimer's Research & Therapy.
[12] G. Beligere,et al. Evaluation of Acute Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Plasma Levels in Traumatic Brain Injury Patients with and without Intracranial Lesions , 2021, Neurotrauma reports.
[13] J. Clarimón,et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia , 2021, Translational Neurodegeneration.
[14] K. Blennow,et al. Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[15] D. Reboussin,et al. Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT) , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[16] F. Schmitt,et al. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study , 2021, The Lancet Neurology.
[17] A. Toga,et al. Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[18] K. Blennow,et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome , 2021, Nature Communications.
[19] K. Blennow,et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[20] John K. Yue,et al. Comparison of GFAP and UCH-L1 Measurements from Two Prototype Assays: The Abbott i-STAT and ARCHITECT Assays , 2021, Neurotrauma reports.
[21] W. M. van der Flier,et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.
[22] K. Blennow,et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.
[23] K. Blennow,et al. Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. , 2020, Journal of Alzheimer's disease : JAD.
[24] H. Hampel,et al. Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases , 2020, Molecular Neurobiology.
[25] K. Blennow,et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.
[26] Nick C Fox,et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study , 2020, Molecular Psychiatry.
[27] K. Blennow,et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[28] S. Lehmann,et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study , 2020, The Lancet.
[29] K. Blennow,et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.
[30] K. Blennow,et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.
[31] J. Diehl-Schmid,et al. Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. , 2020, Journal of proteome research.
[32] J. Karlawish,et al. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results , 2020, PloS one.
[33] Nick C Fox,et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.
[34] Philip S. Insel,et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.
[35] James G. Bollinger,et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.
[36] N. Martin,et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[37] K. Blennow,et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.
[38] A. Ludolph,et al. CNS phenotype in X linked Charcot- Marie-Tooth disease , 2018, Journal of Neurology Neurosurgery & Psychiatry.
[39] C. Jack,et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.
[40] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[41] T. Tokuda,et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome , 2017, Molecular Neurodegeneration.
[42] K. Blennow,et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis , 2017, The Lancet Neurology.
[43] K. Fliessbach,et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias , 2017, Neurology.
[44] K. Blennow,et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy , 2016, Annals of clinical and translational neurology.
[45] A. Nakamura,et al. Novel plasma biomarker surrogating cerebral amyloid deposition , 2014, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[46] Ludwig Kappos,et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.
[47] D. Perl,et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. , 2008, Archives of neurology.